Full-Time
Confirmed live in the last 24 hours
Non-invasive cardiac testing technology provider
$100k - $120k/yr
Senior
Remote in USA
Candidates must be based in the United States and willing to work in PST time zone.
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries, aiding physicians in diagnosing and treating heart disease. The technology allows for detailed analysis through various components, including FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner. This approach eliminates the need for invasive procedures, making cardiovascular care safer and more efficient for both patients and healthcare providers. HeartFlow's products have received FDA clearance and are available in the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a comprehensive analysis that enhances treatment planning while reducing risks and costs associated with traditional diagnostic methods. The company's goal is to improve cardiovascular care by offering advanced, non-invasive solutions that support better health outcomes.
Company Size
501-1,000
Company Stage
Debt Financing
Total Funding
$1B
Headquarters
Redwood City, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Stock Options
401(k) Company Match
HeartFlow has filed a notice for an exempt offering of securities to raise $50 million in new debt financing. This filing with the U.S. Securities and Exchange Commission is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, specifically under Rule 504 or 506 of Regulation D or Section 4(a)(5). The notice must be filed within 15 days after the first sale of securities in the offering.
Heartflow, Inc. announced a $98 million convertible notes financing led by its parent company, Heartflow Holding, Inc. New and existing investors, including Fidelity Management, Janus Henderson, and Bain Capital, participated. The funds will support R&D to advance Heartflow's AI-driven coronary care platform. Heartflow's technology, recognized for innovation, aims to improve CAD diagnosis and management. The platform has been used for over 400,000 patients globally.
Heartflow was recently named one of Fast Company's Most Innovative Companies in Medical Devices for 2025 and won the Innovation in Cardiac Imaging award at the Global Cardiovascular Awards 2025.
HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers
HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.